What do experts think we should do to achieve brain health?

Neuroscience and Biobehavioral Reviews

Volumn 43, Issue , 2014, Pages 240-258

  Sahakian, Barbara J ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Expert ideas in neuroscience, innovation, technology and brain health; Neuropsychiatric disorders

Indexed keywords

ATOMOXETINE; CHOLINESTERASE INHIBITOR; METHYLPHENIDATE; MODAFINIL; SOLANEZUMAB;

AGING; ALZHEIMER DISEASE; ATTENTION DEFICIT DISORDER; BRAIN FUNCTION; DISEASE SEVERITY; DISTRESS SYNDROME; DRUG APPROVAL; EARLY DIAGNOSIS; HEALTH CARE COST; HUMAN; MEDICAL RESEARCH; MENTAL DISEASE; MENTAL HEALTH; NATIONAL HEALTH SERVICE; NEUROIMAGING; NEUROPROTECTION; NEUROSCIENCE; NOTE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; SCHIZOPHRENIA; UNITED KINGDOM; WELLBEING; WORKING MEMORY; ANIMAL; BRAIN; BRAIN MAPPING; IMAGE PROCESSING; PHYSIOLOGY; THINKING;

ANIMALS; BIOMEDICAL RESEARCH; BRAIN; BRAIN MAPPING; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; THINKING;

EID: 84901823635     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2014.04.002     Document Type: Note

References (43)

1. Alloway T.P., Alloway R.G. Investigating the predictive roles of working memory and IQ in academic attainment. Journal Experimental Child Psychology 2010, 106:20-29.
2. Amminger G.P., Edwards J., Brewer W.J., Harrigan S., McGorry P.D. Duration of untreated psychosis and cognitive deterioration in first-episode schizophrenia. Schizophrenia Research 2002, 54:223-230.
3. Beddington J., Cooper C.L., Field J., et al. The mental wealth of nations. Nature 2008, 455:1057-1060.
4. Chamberlain S.R., del Campo N., Dowson J., et al. Atomoxetine improved response inhibition in adults with attention deficit/hyperactivity disorder. Biological Psychiatry 2007, 62:977-984.
5. Chamberlain S.R., Hampshire A., Müller U., et al. Atomoxetine modulates right inferior frontal activation during inhibitory control: a pharmacological functional magnetic resonance imaging study. Biological Psychiatry 2009, 65:550-555.
6. Chamberlain S.R., Muller U., Blackwell A.D., et al. Neurochemical modulation of response inhibition and probabilistic learning in humans. Science 2010, 311:861-863.
7. Chamberlain S.R., Robbins T.W., Sahakian B.J. The neurobiology of attention-deficit/hyperactivity disorder. Biological Psychiatry 2007, 61:1317-1319.
8. Chamberlain S., Sahakian B. Attention deficit hyperactivity disorder has serious and immediate implications. Educational Journal 2006, 94:35-37.
9. Chang W.C., Hui C.L.M., Tang J.Y.M., et al. Impacts of duration of untreated psychosis on cognition and negative symptoms in first-episode schizophrenia: a 3-year prospective follow-up study. Psychological Medicine 2013, 1-11. 10.1017/S0033291712002838.
10. Collins P.Y., Patel V., Joestl S.S., et al. Grand challenges in global mental health. Nature 2011, 475:1-10.
11. Department of Health (DOH) No health without mental health-a cross-government mental health outcomes strategy for people of all ages. Supporting document-the economic case for improving efficiency and quality in mental health 2011, http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_123993.pdf.
12. Eadie B.D., Redila V.A., Christie B.R. Voluntary exercise alters the cytoarchitecture of the adult dentate gyrus by increasing cellular proliferation, dendritic complexity, and spine density. Journal of Comparative Neurology 2005, 486:39-47.
13. Eagger S.A., Levy R., Sahakian B.J. Tacrine in Alzheimer's disease. The Lancet 1991, 337:989-992.
14. Fava M. Diagnosis and definition of treatment-resistant depression. Biological Psychiatry 2003, 53:649-659.
15. Fava M., Davidson K.G. Definition and epidemiology of treatment-resistant depression. The Psychiatric Clinics of North America 1996, 19:179-200.
16. Fineberg N.A., Haddad P.M., Carpenter L., et al. The size, burden and cost of brain disorders in the UK. Journal of Psychopharmacology 2013, doi: http://dx.doi.org/10.1177/0269881113495118.
17. Getsios D., Blume S., Ishak K.J., Maclaine G., Hernández L. An economic evaluation of early assessment for Alzheimer's disease in the United Kingdom. Alzheimer's and Dementia 2012, 8:22-30.
18. Gogtay N., Giedd J.N., Lusk L., et al. Dynamic mapping of human cortical development during childhood through early adulthood. Proceedings of the National Academy of Science United States of America 2004, 101:8174-8179.
19. Gould E., Beylin A., Tanapat P., Reeves A., Shors T.J. Learning enhances adult neurogenesis in the hippocampal formation. Nature Neuroscience 1999, 2:260-265.
20. Health Economics Research Group, Office of Health Economics, RAND Europe Medical Research: What's it Worth? Estimating the Economic Benefits from Medical Research in the UK 2008, UK Evaluation Forum, London.
21. Howard R., McShane R., Lindesay J., et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease. New England Journal of Medicine 2012, 366:893-903.
22. Insel T.R., Sahakian B.J., et al. A plan for mental illness. Nature 2012, 483:269.
23. Jenkins R., et al. Foresight Mental Capacity and Wellbeing Project. Mental Health: Future Challenges 2008, Government Office for Science.
24. Joyce E., Hutton S., Mutsatsa S., et al. Executive dysfunction in first-episode schizophrenia and relationship to duration of untreated psychosis: the West London Study. The British Journal of Psychiatry 2002, 181:s38-s44.
25. Kessler R.C., Petukhova M., Sampson N.A., Zaslavsky A.M., Wittchen H.U. Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. International Journal of Methods in Psychiatric Research 2012, 21:169-184.
26. Klingberg T. Training and plasticity of working memory. Trends in Cognitive Sciences 2010, 14:317-324.
27. Lawrence A., Clark L., Labuzetta J.N., Vyakarnam S., Sahakian B. The innovative brain. Nature 2008, 456:168-169.
28. Lynch G., Sahakian B.J., Collingridge G.L., et al. Cognitive enhancers: molecules, mechanisms and minds. Neuropharmacology 2013, 64.
29. McNab F., Varrone A., Farde L., et al. Changes in cortical dopamine D1 receptor binding associated with cognitive training. Science 2009, 323:800-802.
30. Mehta M.A., Owen A.M., Sahakian B.J., et al. Methylphenidate enhances working memory by modulating discrete frontal and parietal lobe regions in the human brain. The Journal of Neuroscience 2000, 20:1-6.
31. Muller U., Rowe J.B., Rittman T., et al. Effects of modafinil on non-verbal cognition, task enjoyment and creative thinking in healthy volunteers. Neuropharmacology 2013, 64:490-495.
32. Olesen P.J., Westerberg H., Klingberg T. Increased prefrontal and parietal activity after training of working memory. Nature Neuroscience 2004, 7:75-79.
33. Olson A.K., Eadie B.D., Ernst C., Christie B.R. Environmental enrichment and voluntary exercise massively increase neurogenesis in the adult hippocampus via dissociable pathways. Hippocampus 2006, 16:250-260.
34. Orrell M., Sahakian B. Education and dementia. British Medical Journal 1995, 310:951-952.
35. Owens M., Goodyer I., Wilkinson P., et al. 5-HTTLPR and exposure to an adverse family environment in the preschool years is associated with emotional processing deficits during adolescence. Public Library of Science One 2012, 7:e48482. doi: 10.1371, Epub Nov 28.
36. Rindermann H. Relevance of education and intelligence at the national level for the economic welfare of people. Intelligence 2008, 36:127-142.
37. Roiser J.P., Elliott R., Sahakian B.J. Cognitive mechanisms of treatment in depression. Neuropsychopharmacology Reviews 2011, 37:1-20.
38. The Royal Society The Scientific Century: Securing our Future Prosperity. RS Policy document 02/10 2010.
39. Sahakian B.J., Malloch G., Kennard C., et al. A UK strategy for mental health and wellbeing. The Lancet 2010, 375:1854-1855.
40. Sahakian B.J., Owen A.M., Morant N.J., et al. Further analysis of the cognitive effects of tetrahydroaminoacridine (THA) in Alzheimer's disease: assessment of attentional and mnemonic function using CANTAB. Psychopharmacology 1993, 110:395-401.
41. Scoriels L., Barnett J.H., Soma P.K., Sahakian B.J., Jones P.B. Effects of modafinil on cognitive functions in first episode psychosis. Psychopharmacology 2012, 220:249-258.
42. Wykes T., Huddy V., Cellard C., McGurk S.R., Czobor P. A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. American Journal of Psychiatry 2011, 168:472-485.
43. Zarate C., Singh J., Carlson P., et al. A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Archives of General Psychiatry 2006, 63:856-864.